# A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

> **NCT06371157** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 469 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** AK104
- **DRUG:** Lenvatinib
- **PROCEDURE:** TACE
- **OTHER:** Placebo for AK104
- **OTHER:** Placebo for Lenvatinib

## Key facts

- **NCT ID:** NCT06371157
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-02
- **Primary completion:** 2025-10-25
- **Final completion:** 2026-05-23
- **Target enrollment:** 469 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06371157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06371157, "A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06371157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*